Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of "Buy" by Analysts

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) has been assigned a consensus rating of "Buy" from the nine brokerages that are covering the firm, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $22.29.

A number of analysts have commented on ZVRA shares. JMP Securities set a $18.00 target price on shares of Zevra Therapeutics in a report on Wednesday, March 12th. Guggenheim boosted their price objective on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, March 13th. Wall Street Zen upgraded Zevra Therapeutics from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Citigroup reiterated an "outperform" rating on shares of Zevra Therapeutics in a research report on Wednesday, May 14th. Finally, HC Wainwright reissued a "buy" rating and set a $20.00 price target on shares of Zevra Therapeutics in a report on Thursday, March 13th.

Zevra Therapeutics Stock Up 3.0%

Zevra Therapeutics stock opened at $9.07 on Friday. Zevra Therapeutics has a one year low of $4.20 and a one year high of $9.76. The stock has a fifty day moving average of $8.16 and a 200 day moving average of $8.06. The company has a debt-to-equity ratio of 1.46, a quick ratio of 2.93 and a current ratio of 3.02. The stock has a market cap of $495.95 million, a PE ratio of -4.77 and a beta of 2.01.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.15. Zevra Therapeutics had a negative net margin of 226.78% and a negative return on equity of 201.05%. The firm had revenue of $20.40 million during the quarter, compared to analyst estimates of $16.96 million. During the same quarter in the prior year, the firm earned ($0.40) EPS. As a group, sell-side analysts predict that Zevra Therapeutics will post -1.95 EPS for the current year.

Institutional Investors Weigh In On Zevra Therapeutics

Institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets purchased a new position in shares of Zevra Therapeutics in the fourth quarter valued at about $53,000. GAMMA Investing LLC lifted its holdings in Zevra Therapeutics by 20,564.1% in the 1st quarter. GAMMA Investing LLC now owns 8,059 shares of the company's stock worth $60,000 after purchasing an additional 8,020 shares in the last quarter. Strs Ohio bought a new position in Zevra Therapeutics in the 1st quarter worth approximately $125,000. Squarepoint Ops LLC boosted its stake in Zevra Therapeutics by 36.1% in the 4th quarter. Squarepoint Ops LLC now owns 16,534 shares of the company's stock worth $138,000 after purchasing an additional 4,384 shares during the period. Finally, ProShare Advisors LLC purchased a new stake in Zevra Therapeutics during the 4th quarter valued at approximately $145,000. Hedge funds and other institutional investors own 35.03% of the company's stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.